This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Launched in 2019, NABP’s SpecialtyPharmacy Accreditation was created to accredit pharmacies providing advanced levels of pharmacy services and disease management tools for patients taking medications that require special handling, storage, and dispensing requirements.
The pandemic has exposed flaws in services for people who can’t easily access a drive-through window for Covid shots or testing or can’t read prescription labels.
PHASE THREE Building-out 340B program “infrastructure” Optimizing the number and quality of 340B eligible contract pharmacies If your health system is managing its own 340B program, there’s something you should know: Your contract pharmacy network is not what it should be. Eight tips for dealing with 340B ESP 1.
Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. Understand, and master, your 340B specialtypharmacy opportunities. The 340B revenue potential of specialtypharmacy is staggering.
Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to $435 million in savings generated for the hospitals and health systems we serve. Arkansas , for instance, recently struck a deal with Novo Nordisk — restoring 340B contract pharmacy discounts while both sides await a forthcoming Appeals Court ruling.
And also, the amount of money that’s being poured into this and with north of $9 billion in 2019. I think that 2018, 2019 I will tell you, I think I’m looking at already 12 to 14 billion is my prediction for the end of 2019 would north of probably 1000 deals going through with a couple of exits as well.
And also, the amount of money that’s being poured into this and with north of $9 billion in 2019. I think that 2018, 2019 I will tell you, I think I’m looking at already 12 to 14 billion is my prediction for the end of 2019 would north of probably 1000 deals going through with a couple of exits as well.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content